Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
-
Narrated by:
-
By:
Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
JAMA Network
This multicenter randomized study examined if 7-day extended-release injectable buprenorphine compared with sublingual buprenorphine to improve treatment engagement at 7 days. It included 1,994 adult patients presenting to the emergency department with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher. In treatment at 7 days, 40.5% were in the extended-release group and 38.5% were in the sublingual buprenorphine group, demonstrating no significant difference between groups. The study concluded that a 7-day extended-release injectable preparation of buprenorphine does not improve treatment engagement.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM